Last Updated:
10 Mar 2026, 03:29:59 PM (IST)
Lupin Limited
NSE: LUPIN BSE: LUPIN
NSE
2,337.40
34.30 (1.49%)
Prev Close
2303.1
Open Price
2318
Volume
1,118,737
Today Low / High
2314.6 / 2358
52 WK Low / High
1795.2 / 2369.5
Range
2,221 - 2,454
BSE
2,340.75
39.05 (1.70%)
Prev Close
2301.7
Open Price
2302.8
Volume
10,556
Today Low / High
2302.8 / 2358
52 WK Low / High
1774 / 2358
Range
2,224 - 2,458
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2337.4 (target range: 2,221 - 2,454), reflecting a change of 34.3 (1.4893%). On the BSE, it is listed at 2340.75 (target range: 2,224 - 2,458), showing a change of 39.05 (1.69657%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
2,275.60
1.56%
27 Feb
2,330.00
-1.21%
26 Feb
2,292.20
1.35%
25 Feb
2,267.20
1.10%
24 Feb
2,252.50
-0.10%
23 Feb
2,220.00
0.96%
20 Feb
2,218.00
0.06%
19 Feb
2,234.00
-0.24%
18 Feb
2,255.00
-1.25%
Lupin Limited Graph
Lupin Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lupin Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,337.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,340.75 | 2,364.16 | 2,127.74 - 2,600.57 |
| 2,387.57 | 1,910.05 - 2,865.08 | ||
| 2,410.97 | 1,687.68 - 3,134.26 | ||
| Bearish Scenario | 2,340.75 | 2,317.34 | 2,085.61 - 2,549.08 |
| 2,293.94 | 1,835.15 - 2,752.72 | ||
| 2,270.53 | 1,589.37 - 2,951.69 |
Overview of Lupin Limited
ISIN
INE326A01037
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
806,341
Market Cap
1,056,272,077,300
Last Dividend
12
Official Website
IPO Date
2001-09-10
DCF Diff
-1,916.95
DCF
4,228
Financial Ratios Every Investor Needs
Stock Dividend of LUPIN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 12 | 12 | 2025-07-25 | 2025-09-10 | |
| 2024-07-16 | July 16, 24 | 8 | 8 | 2024-07-16 | 2024-09-01 | |
| 2023-07-14 | July 14, 23 | 4 | 4 | 2023-07-14 | 2023-09-02 | |
| 2022-07-14 | July 14, 22 | 4 | 4 | 2022-07-15 | 2022-09-02 | |
| 2021-07-27 | July 27, 21 | 6.5 | 6.5 | 2021-07-28 | 2021-08-17 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 22,707.90 Cr | 7,381.04 Cr | 15,326.86 Cr | 0.6750 | 1,767.19 Cr | 0.00 Cr | 9,480.10 Cr | 3,281.62 Cr | 71.95 | 5,050.67 Cr | 0.1445 |
| 2024-03-31 | 20,010.82 Cr | 7,111.64 Cr | 12,899.18 Cr | 0.6446 | 1,526.50 Cr | 0.00 Cr | 7,779.72 Cr | 1,914.48 Cr | 42.05 | 3,627.22 Cr | 0.0957 |
| 2023-03-31 | 16,641.66 Cr | 7,232.15 Cr | 9,409.51 Cr | 0.5654 | 1,280.01 Cr | 0.00 Cr | 4,945.03 Cr | 430.08 Cr | 9.46 | 1,573.41 Cr | 0.0258 |
| 2022-03-31 | 16,405.48 Cr | 6,900.07 Cr | 9,505.41 Cr | 0.5794 | 1,402.36 Cr | 0.00 Cr | 5,022.03 Cr | -1,528.04 Cr | -33.65 | 1,966.02 Cr | -0.0931 |
| 2021-03-31 | 15,162.96 Cr | 5,744.50 Cr | 9,418.46 Cr | 0.6211 | 1,432.42 Cr | 0.00 Cr | 5,071.44 Cr | 1,216.53 Cr | 26.84 | 2,524.12 Cr | 0.0802 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,543.69 Cr | 29,204.88 Cr | 11,910.53 Cr | 17,203.5000 Cr | 5,447.77 Cr | 3,904.08 Cr | 5,476.35 Cr | 5,613.60 Cr | 0.00 Cr | 204.51 Cr | 1,301.31 Cr | 8,961.3900 Cr |
| 2024-03-31 | 1,187.60 Cr | 23,997.18 Cr | 9,623.73 Cr | 14,290.2900 Cr | 2,921.77 Cr | 1,734.17 Cr | 4,953.90 Cr | 5,494.22 Cr | 42.89 Cr | 189.40 Cr | -643.80 Cr | 8,501.5000 Cr |
| 2023-03-31 | 1,277.82 Cr | 22,955.93 Cr | 10,413.11 Cr | 12,464.5000 Cr | 4,541.52 Cr | 3,309.71 Cr | 4,491.76 Cr | 5,539.84 Cr | 63.16 Cr | 160.02 Cr | -498.44 Cr | 9,265.3700 Cr |
| 2022-03-31 | 1,089.92 Cr | 21,821.22 Cr | 9,599.24 Cr | 12,153.2700 Cr | 4,158.38 Cr | 3,068.46 Cr | 4,630.73 Cr | 5,397.30 Cr | 38.60 Cr | 134.24 Cr | -933.71 Cr | 8,276.4400 Cr |
| 2021-03-31 | 1,734.61 Cr | 23,610.44 Cr | 9,752.33 Cr | 13,803.1400 Cr | 5,129.08 Cr | 3,394.47 Cr | 4,092.01 Cr | 5,234.44 Cr | 0.00 Cr | 143.69 Cr | -2,378.94 Cr | 8,436.0900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,999.9400 Cr | -4,171.8900 Cr | 1,731.8800 Cr | 1,317.5100 Cr | 559.9300 Cr | 1,543.6900 Cr | -1,682.4300 Cr | 3,281.6200 Cr | 2,427.7400 Cr | -365.3100 Cr | -541.2400 Cr |
| 2024-03-31 | 3,648.3600 Cr | -1,712.2000 Cr | -2,184.2100 Cr | 2,719.4600 Cr | -248.0500 Cr | 983.7600 Cr | -928.9000 Cr | 2,422.2700 Cr | -1,617.1300 Cr | -182.8000 Cr | -440.1500 Cr |
| 2023-03-31 | 1,896.9800 Cr | -1,286.7700 Cr | -337.2500 Cr | 397.6200 Cr | 273.2200 Cr | 1,264.5900 Cr | -1,499.6200 Cr | 716.4900 Cr | 172.8100 Cr | -182.5000 Cr | 195.4400 Cr |
| 2022-03-31 | 367.3100 Cr | 1,292.2300 Cr | -1,572.3200 Cr | -537.7700 Cr | 87.2200 Cr | 1,013.4400 Cr | -905.0800 Cr | -1,372.2100 Cr | -1,078.7000 Cr | -295.0900 Cr | -499.3300 Cr |
| 2021-03-31 | 1,821.7600 Cr | -1,239.5800 Cr | -1,885.2700 Cr | 1,144.1400 Cr | -1,303.0900 Cr | 926.2200 Cr | -677.6200 Cr | 1,676.4500 Cr | -1,367.7100 Cr | -272.3200 Cr | -657.4200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 7,100.45 Cr | 1,878.13 Cr | 5,222.32 Cr | 0.7355 | 1,896.53 Cr | 1,175.55 Cr | 25.74 | 1,949.98 Cr | 0.1656 |
| 2025-09-30 | 7,047.51 Cr | 3,247.10 Cr | 3,800.41 Cr | 0.5393 | 1,820.83 Cr | 1,477.92 Cr | 32.36 | 2,431.33 Cr | 0.2097 |
| 2025-06-30 | 6,268.34 Cr | 1,771.93 Cr | 4,496.41 Cr | 0.7173 | 3,413.41 Cr | 1,219.03 Cr | 26.70 | 1,678.90 Cr | 0.1945 |
| 2025-03-31 | 5,667.13 Cr | 2,224.99 Cr | 3,442.14 Cr | 0.6074 | 558.33 Cr | 772.52 Cr | 16.93 | 953.25 Cr | 0.1363 |
| 2024-12-31 | 5,767.71 Cr | 1,721.55 Cr | 4,046.16 Cr | 0.7015 | 3,061.77 Cr | 855.16 Cr | 18.75 | 1,392.86 Cr | 0.1483 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 3,040.22 Cr | 3,241.87 Cr | 6,282.09 Cr | 6,294.98 Cr | 5,954.96 Cr | 20,265.92 Cr | 5,848.43 Cr | 33,500.44 Cr | 13,772.07 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 2,989.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -17,294.35 Cr |
| 2025-03-31 | 2,755.24 Cr | 1,446.20 Cr | 4,201.44 Cr | 5,502.12 Cr | 5,476.35 Cr | 16,798.58 Cr | 5,613.60 Cr | 29,204.88 Cr | 11,910.53 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,912.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -15,719.69 Cr |
| 2024-09-30 | 1,413.88 Cr | 1,498.43 Cr | 2,912.31 Cr | 5,118.98 Cr | 5,284.74 Cr | 15,020.11 Cr | 5,450.75 Cr | 25,481.96 Cr | 9,762.27 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,219.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 772.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 855.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 852.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 801.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-08-27 | August 27, 10 | 5:1 |
| 2006-08-11 | August 11, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
President of Corporate Development
Fabrice Egros
Gender: Not Specified
Year Born: 1963
Chief Scientific Officer
Shahin Fesharaki
Gender: Not Specified
Year Born:
Company Secretary & Compliance Officer
Amit Kumar Gupta
Gender: male
Year Born:
Chief Technical Operations Officer
Christoph Funke
Gender: male
Year Born:
MD & Executive Director
Nilesh Deshbandhu Gupta
Gender: male
Year Born: 1974
Executive Director, Global Chief Financial Officer, CRO & Head of API Plus SBU and IT
Ramesh Swaminathan
Gender: male
Year Born: 1966
Sr. Vice President of Investor Relations and M&A
Ravi Agrawal
Gender: male
Year Born:
President of Global Human Resources
Yashwant S. Mahadik
Gender: male
Year Born: 1967
Vice President & Global Head of Corporate Communications
Rajalakshmi Azariah
Gender: female
Year Born:
CEO & Executive Director
Vinita D. Gupta
Gender: female
Year Born: 1968
FAQs about Lupin Limited
Who is the CEO of the company?
The CEO is Vinita D. Gupta.
What is the current market price of the stock?
The current price is ₹2,311.10.
What is the 52-week price range?
The range is ₹1795.2-2336.3.
What is the market capitalization of the company?
The market capitalization is ₹105,627.21 crores.
What is the dividend yield?
The dividend yield is 0.52%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 22.72.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lupin Limited (ISIN: INE326A01037) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹105,627.21 crores and an average daily volume of 806,341 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹12.